[{"address1": "The Omeros Building", "address2": "201 Elliott Avenue West", "city": "Seattle", "state": "WA", "zip": "98119", "country": "United States", "phone": "206 676 5000", "website": "https://www.omeros.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases. The company's lead products candidate is the Narsoplimab (OMS721/MASP-2) for the treatment of hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); and in Phase II clinical trial to treat COVID-19 and acute respiratory distress syndrome. It also develops OMS1029 that has completed phase I clinical trials for mannan-binding lectin-associated serine protease 2 (MASP-2) and lectin pathway disorders; zaltenibart that is in phase 3 clinical trials for Paroxysmal nocturnal hemoglobinuria; in phase 2 clinical trial for the treatment complement 3 glomerulopathy, and other alternative pathway disorders; and OMS527 that is in phase I clinical trials for addictions and compulsive disorders, and movement disorders, as well as cocaine use disorder. In addition, the company's products under preclinical development comprise MASP-2, a pro-inflammatory protein target for the treatment of lectin pathway disorders; MASP-3 small-molecule inhibitors for alternative pathway disorders; and Adoptive T-Cell and Immunostimulator Combination Therapies, and Oncotoxins and Immunomodulators for the treatment of various cancers. Omeros Corporation was incorporated in 1994 and is headquartered in Seattle, Washington.", "fullTimeEmployees": 202, "companyOfficers": [{"maxAge": 1, "name": "Dr. Gregory A. Demopulos M.D.", "age": 65, "title": "Co-Founder, Chairman, CEO & President", "yearBorn": 1959, "fiscalYear": 2024, "totalPay": 1912408, "exercisedValue": 0, "unexercisedValue": 5469956}, {"maxAge": 1, "name": "Dr. George A. Gaitanaris M.D., Ph.D.", "age": 67, "title": "Chief Scientific Officer & VP of Science", "yearBorn": 1957, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Peter W. Williams", "age": 56, "title": "Vice President of Human Resources", "yearBorn": 1968, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Catherine A. Melfi Ph.D.", "age": 65, "title": "Chief Regulatory Officer & VP of Regulatory Affairs and Quality Systems", "yearBorn": 1959, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Nadia  Dac", "age": 54, "title": "VP & Chief Commercial Officer", "yearBorn": 1970, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Andreas  Grauer M.D.", "age": 63, "title": "VP & Chief Medical Officer", "yearBorn": 1961, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. David W. Ghesquiere", "age": 57, "title": "VP & Chief Business Development Officer", "yearBorn": 1967, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 7, "boardRisk": 9, "compensationRisk": 10, "shareHolderRightsRisk": 5, "overallRisk": 9, "governanceEpochDate": 1746057600, "compensationAsOfEpochDate": 1735603200, "executiveTeam": [], "maxAge": 86400, "priceHint": 2, "previousClose": 6.35, "open": 6.41, "dayLow": 6.23, "dayHigh": 6.5751, "regularMarketPreviousClose": 6.35, "regularMarketOpen": 6.41, "regularMarketDayLow": 6.23, "regularMarketDayHigh": 6.5751, "payoutRatio": 0.0, "beta": 2.424, "forwardPE": -2.7905984, "volume": 194040, "regularMarketVolume": 194040, "averageVolume": 634800, "averageVolume10days": 446090, "averageDailyVolume10Day": 446090, "bid": 6.46, "ask": 6.6, "bidSize": 1, "askSize": 1, "marketCap": 380736896, "fiftyTwoWeekLow": 3.0, "fiftyTwoWeekHigh": 13.6, "fiftyDayAverage": 7.6338, "twoHundredDayAverage": 6.81145, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": 701850752, "profitMargins": 0.0, "floatShares": 55488186, "sharesOutstanding": 58305800, "sharesShort": 10706376, "sharesShortPriorMonth": 9501201, "sharesShortPreviousMonthDate": 1741910400, "dateShortInterest": 1744675200, "sharesPercentSharesOut": 0.1844, "heldPercentInsiders": 0.044180002, "heldPercentInstitutions": 0.46117002, "shortRatio": 12.29, "shortPercentOfFloat": 0.1928, "impliedSharesOutstanding": 58305800, "bookValue": -3.146, "lastFiscalYearEnd": 1735603200, "nextFiscalYearEnd": 1767139200, "mostRecentQuarter": 1735603200, "netIncomeToCommon": -182628992, "trailingEps": -3.14, "forwardEps": -2.34, "enterpriseToEbitda": -4.17, "52WeekChange": 0.78370786, "SandP52WeekChange": 0.08001411, "quoteType": "EQUITY", "currentPrice": 6.53, "targetHighPrice": 36.0, "targetLowPrice": 36.0, "targetMeanPrice": 36.0, "targetMedianPrice": 36.0, "recommendationMean": 2.33333, "recommendationKey": "buy", "numberOfAnalystOpinions": 1, "totalCash": 90132000, "totalCashPerShare": 1.552, "ebitda": -168308000, "totalDebt": 423276992, "quickRatio": 1.231, "currentRatio": 1.686, "returnOnAssets": -0.32284, "grossProfits": -71549000, "freeCashflow": -114679128, "operatingCashflow": -148803008, "grossMargins": 0.0, "ebitdaMargins": 0.0, "operatingMargins": 0.0, "financialCurrency": "USD", "symbol": "OMER", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "shortName": "Omeros Corporation", "longName": "Omeros Corporation", "marketState": "REGULAR", "earningsTimestamp": 1743451320, "earningsTimestampStart": 1747133940, "earningsTimestampEnd": 1747656000, "earningsCallTimestampStart": 1743453000, "earningsCallTimestampEnd": 1743453000, "isEarningsDateEstimate": true, "epsTrailingTwelveMonths": -3.14, "epsForward": -2.34, "epsCurrentYear": -2.27667, "priceEpsCurrentYear": -2.8682244, "fiftyDayAverageChange": -1.1037998, "fiftyDayAverageChangePercent": -0.14459376, "twoHundredDayAverageChange": -0.2814498, "twoHundredDayAverageChangePercent": -0.0413201, "priceToBook": -2.0756516, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "averageAnalystRating": "2.3 - Buy", "cryptoTradeable": false, "regularMarketChangePercent": 2.8346505, "regularMarketPrice": 6.53, "exchange": "NGM", "messageBoardId": "finmb_32388", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EDT", "gmtOffSetMilliseconds": -14400000, "market": "us_market", "esgPopulated": false, "regularMarketChange": 0.1800003, "regularMarketDayRange": "6.23 - 6.5751", "fullExchangeName": "NasdaqGM", "averageDailyVolume3Month": 634800, "fiftyTwoWeekLowChange": 3.5300002, "fiftyTwoWeekLowChangePercent": 1.1766667, "fiftyTwoWeekRange": "3.0 - 13.6", "fiftyTwoWeekHighChange": -7.07, "fiftyTwoWeekHighChangePercent": -0.51985294, "fiftyTwoWeekChangePercent": 78.37079, "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 1255008600000, "corporateActions": [], "regularMarketTime": 1746724125, "displayName": "Omeros", "trailingPegRatio": null, "__fetch_time": "2025-05-08"}]